Schistosoma Haematobium Infections and Praziquantel
The purpose of this study is to evaluate the impact of praziquantel for the treatment of Schistosoma haematobium infection among schoolchildren in Al Salamania in Central Sudan.
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Schistosoma Haematobium Infections Among Schoolchildren in Central Sudan One Year After Treatment With Praziquantel|
- cure rate [ Time Frame: one year ] [ Designated as safety issue: No ]The reduction of the prevalence and intensity of S.haematobium infection following a single dose of praziquantel40mg/kg
- reduction in the intensity of infection by [ Time Frame: one year ] [ Designated as safety issue: No ]will a single dose of PZQ significantly reduced intensity of infection of S. haematobium infection 1 year after treatment
|Study Start Date:||August 2008|
|Study Completion Date:||September 2012|
|Primary Completion Date:||August 2012 (Final data collection date for primary outcome measure)|
tablet single dose
praziquantel 40 mg/kg oral tablets
A longitudinal study will be conducted to evaluate the impact of praziquantel for the treatment of Schistosoma haematobium infection among schoolchildren in Al Salamania in Central Sudan. A cohort of schoolchildren (6-15 years of age) was investigated before and 1 year after treatment with a single dose of praziquantel 40mg/kg.